King Pharmaceuticals, Inc. (NYSE:KG)

Price is now 14.15....
Pfizer will acquire King Pharma for $14.25 per share.

watch

Recently had a slight setback with their drug Acurox, FDA rejected it but there is still a chance that it will get passed if the regulator says its ok. Right now they plan on submitting a new application in early 2011 with a new version of the drug that will have much better odds of getting approved. This company might not have much growth short term, but in the long term should be very profitable. They have a large number of drugs which should boost numbers in the next couple of years. Also a court ruling is causing one of the generic competitors Skelaxin off the market for now.

Hypothyroidism based weightloss craze mixed with universal mandated healthcare = big bucks for companies that manufacture thyroid hormone drugs.

new technology they have fixed it to prevent abuse of over doing for affect. docs will be more likely to prefer this med over others that can be abused for recreation purposes. docs will flock to this med!

Good looking company....

New meds

King pharm has been performing well for me over the past month

At 0.3, low debt to equity reducing risk in these tight money times. Forward P/E of 6.9x versus industry P/E of 10.8x. Price to sales of 1.0x versus industry of 2.4x. These numbers would seem to make KG an attractive take over target to a larger Pharma.

While two of King's Skelaxin patents have been invalidated and may result in a generic release, thier integration of AlphaPharma should more than offset any loss market in Skelaxin while also offering some synergistic cost savings.

Been heading south bound to head back up

Pharma in rough times, MFI. Smaller cap than I wanted, but we'll give it a try.

New Pain Meds = high profits!

They have had some rough times in the past, but these guys sell a lot of generic drugs.

price/book =1.. solid numbers

magicformulainvesting.com screen at $153M market cap, top 25 companies on June 26, 2008

increase in businesses offering fixed price prescriptions will boost near term demand for generics.

King Pharmaceuticals KG has been hurt by the loss of a patent dispute last year for the key ingredient in its hypertension drug Altace. The result has been generic competition for the drug much sooner than anticipated and this is having a negative effect on revenues and margins. As a result King has laid off 20% of its work and refocused its efforts on the neuroscience, hospital and acute care markets. The neuroscience division in particular could be very attractive should they receive FDA approval for their abuse resistant pain drug Remoxy. They hope to have the drug to market by 2009 and it is a potential blockbuster. The stock trades just off its 52-week lows and has a bulletproof balance sheet with over 60% of the stock price in cash. The EV/EBITDA ratio is just 1.5 and equally attractive to the asset-loving side of me, it trading at 85% of book value. It is worth a look at these levels. Tim Melvin - thestreet.com

The King of... something.

valuepick